My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$IBM {{ '2016-07-18T20:47:04+0000' | timeago}} • Announcement

During 2Q16, $IBM's Cognitive Solutions revenue rose 3.5% with Cloud revenue within the segment up 54%. The company's other segments Global Business Services, Technology Services & Cloud Platforms, Systems, and Global Financing revenues all fell 2%, 0.5%, 23.2% and 11.3% respectively, during the quarter impacting total revenues of the firm.

User Melwyn Jones {{ '2016-10-28T17:16:30+0000' | timeago}}

$CVX posts first profit in a year. Right time to get some shares? My question is, will it sustain this turnaround?

User Josh Allan {{ '2016-10-27T15:39:01+0000' | timeago}}

Jeff Bezos, my inspiration next to Steve Jobs is going to review the Everything Store $AMZN's financial results today after hours. As an investor/user, I like Amazon Prime and it's success over several parts of the world. What's your take on Amazon?

User RC xNair {{ '2016-10-27T13:31:32+0000' | timeago}}

Of all the Wall St firms out there, Goldman Sachs $GS is the most revered for the way they're run - hiring the best, highly competitive, a closely-knit peer group and making tons of profits for the shareholders. An interesting interview of its CEO Llyod Blankfein by Carlyle groups chief David Rubenstein

User Ramesh Raju {{ '2016-10-27T10:38:07+0000' | timeago}}

Deutsche Bank posts Q3 net profit of 278 million euros.

User Vishnu Beri {{ '2016-10-27T01:52:28+0000' | timeago}}

Great results from $TSLA, however the question remains if Tesla can continue to scale up to produce the cars in the quantity it promises. Model 3 numbers need to be in multiples of what they are producing right now. Wish them the best, will keep an eye as I am still not convinced that they can scale easily.

$PSX {{ '2016-10-28T18:10:53+0000' | timeago}} • Webcast

$PSX's FY16 capital expenditures are expected to be approx. $3Bil, down from $3.9Bil initially budgeted. This reduction is primarily driven by Midstream project cancellations and deferrals, as well as the impact of project financing. FY17 CapEx is expected to be less than $3Bil.

$ALXN {{ '2016-10-28T18:07:35+0000' | timeago}} • Webcast

With growing in-line business and robust pipeline, $ALXN sees long-term sustainable revenue growth through the end of this decade and beyond. The company said it will continue to accelerate its operating margins to 48-49% in 2018 and beyond, through continued top-line growth and expense discipline.

$ALXN {{ '2016-10-28T18:05:15+0000' | timeago}} • Webcast

$ALXN continues to build and strengthen global patent position for both Soliris and ALXN1210. In 3Q16, new U.S. patent was issued for treating kidney affecting disease, atypical hemolytic-uremic syndrome (aHUS), with Soliris that is valid till 2032. $ALXN sees additional patents relating to Soliris over next 12-18 months.

$WY {{ '2016-10-28T18:03:01+0000' | timeago}} • Webcast

$WY has $1.7Bil drawn on the term loan. As it starts closing on the Cellulose Fibers transaction, the company will start paying that down. The company expects this to be paid down hopefully by year-end 2016 or soon around that time.

$WY {{ '2016-10-28T18:00:37+0000' | timeago}} • Webcast

In 2017, $WY will continue to benefit from its cost and operational synergies, continued OpEx improvements and stronger housing markets. The company will be working closely with its Board to determine the right level of dividend going forward.